Last reviewed · How we verify

NCT03823287

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Completed Phase 3 Results posted Last updated 23 July 2025
What this trial tests

Phase 3 trial testing Faricimab in Wet Macular Degeneration in 671 participants. Completed in 18 January 2022.

Timeline
19 February 2019
Primary endpoint
26 October 2020
18 January 2022

Quick facts

Lead sponsorHoffmann-La Roche
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment671
Start date19 February 2019
Primary completion26 October 2020
Estimated completion18 January 2022
Sites161 locations across Italy, Japan, Netherlands, Russia, United Kingdom, Israel, Germany, Hungary

Drugs / interventions tested

Conditions studied

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

50 and older, any sex, with Wet Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 Primary · From Baseline through Week 48

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covarianc

GroupValue95% CI
Arm A: Faricimab5.84.6 – 7.1
Arm B: Aflibercept5.13.9 – 6.4
Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 Secondary · From Baseline through Week 60

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covarianc

GroupValue95% CI
Arm A: Faricimab5.44.0 – 6.8
Arm B: Aflibercept4.63.3 – 6.0
Change From Baseline in BCVA in the Study Eye Over Time Secondary · Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥74, 73-55, and ≤54 letters), baseline LLD (\<33 and ≥33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covarianc

Week 4
GroupValue95% CI
Arm A: Faricimab4.03.2 – 4.8
Arm B: Aflibercept3.62.8 – 4.4
Week 8
GroupValue95% CI
Arm A: Faricimab5.54.6 – 6.4
Arm B: Aflibercept4.53.6 – 5.4
Week 12
GroupValue95% CI
Arm A: Faricimab6.45.5 – 7.4
Arm B: Aflibercept5.34.4 – 6.2
Week 16
GroupValue95% CI
Arm A: Faricimab6.85.8 – 7.8
Arm B: Aflibercept5.24.2 – 6.2
Week 20
GroupValue95% CI
Arm A: Faricimab6.65.5 – 7.6
Arm B: Aflibercept4.93.9 – 6.0
Week 24
GroupValue95% CI
Arm A: Faricimab6.45.2 – 7.5
Arm B: Aflibercept5.14.0 – 6.3
Week 28
GroupValue95% CI
Arm A: Faricimab6.25.1 – 7.3
Arm B: Aflibercept5.64.5 – 6.7
Week 32
GroupValue95% CI
Arm A: Faricimab6.24.9 – 7.4
Arm B: Aflibercept5.13.8 – 6.3
Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 Secondary · Baseline, average of Weeks 40, 44, and 48

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters,

Gaining ≥15 Letters
GroupValue95% CI
Arm A: Faricimab20.015.6 – 24.4
Arm B: Aflibercept15.711.9 – 19.6
Gaining ≥10 Letters
GroupValue95% CI
Arm A: Faricimab37.131.7 – 42.4
Arm B: Aflibercept31.726.7 – 36.8
Gaining ≥5 Letters
GroupValue95% CI
Arm A: Faricimab59.253.7 – 64.7
Arm B: Aflibercept58.052.6 – 63.5
Gaining ≥0 Letters
GroupValue95% CI
Arm A: Faricimab75.670.8 – 80.3
Arm B: Aflibercept76.872.1 – 81.4
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 Secondary · Baseline, average of Weeks 52, 56, and 60

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters,

GroupValue95% CI
Arm A: Faricimab19.215.0 – 23.5
Arm B: Aflibercept16.612.5 – 20.6
Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time Secondary · Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combine

Week 4
GroupValue95% CI
Arm A: Faricimab10.16.9 – 13.2
Arm B: Aflibercept6.33.8 – 8.8
Week 8
GroupValue95% CI
Arm A: Faricimab13.710.1 – 17.3
Arm B: Aflibercept8.15.3 – 10.9
Week 12
GroupValue95% CI
Arm A: Faricimab16.712.8 – 20.5
Arm B: Aflibercept10.17.0 – 13.1
Week 16
GroupValue95% CI
Arm A: Faricimab17.713.7 – 21.6
Arm B: Aflibercept13.410.0 – 16.9
Week 20
GroupValue95% CI
Arm A: Faricimab19.114.9 – 23.2
Arm B: Aflibercept12.79.1 – 16.2
Week 24
GroupValue95% CI
Arm A: Faricimab22.117.4 – 26.7
Arm B: Aflibercept13.39.6 – 17.0
Week 28
GroupValue95% CI
Arm A: Faricimab20.816.4 – 25.2
Arm B: Aflibercept16.212.1 – 20.3
Week 32
GroupValue95% CI
Arm A: Faricimab21.617.0 – 26.1
Arm B: Aflibercept15.111.3 – 18.9
Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time Secondary · Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combine

Week 4
GroupValue95% CI
Arm A: Faricimab20.116.0 – 24.2
Arm B: Aflibercept16.012.3 – 19.7
Week 8
GroupValue95% CI
Arm A: Faricimab28.623.9 – 33.3
Arm B: Aflibercept25.320.9 – 29.8
Week 12
GroupValue95% CI
Arm A: Faricimab31.426.5 – 36.3
Arm B: Aflibercept30.325.5 – 35.1
Week 16
GroupValue95% CI
Arm A: Faricimab36.931.8 – 41.9
Arm B: Aflibercept31.927.0 – 36.7
Week 20
GroupValue95% CI
Arm A: Faricimab39.134.0 – 44.2
Arm B: Aflibercept30.325.4 – 35.2
Week 24
GroupValue95% CI
Arm A: Faricimab41.436.0 – 46.9
Arm B: Aflibercept34.028.7 – 39.3
Week 28
GroupValue95% CI
Arm A: Faricimab38.933.5 – 44.3
Arm B: Aflibercept34.829.5 – 40.1
Week 32
GroupValue95% CI
Arm A: Faricimab38.633.2 – 44.0
Arm B: Aflibercept32.427.2 – 37.7
Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time Secondary · Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combine

Week 4
GroupValue95% CI
Arm A: Faricimab47.642.3 – 52.8
Arm B: Aflibercept45.640.4 – 50.9
Week 8
GroupValue95% CI
Arm A: Faricimab57.852.5 – 63.0
Arm B: Aflibercept52.347.2 – 57.5
Week 12
GroupValue95% CI
Arm A: Faricimab61.556.3 – 66.8
Arm B: Aflibercept55.049.7 – 60.2
Week 16
GroupValue95% CI
Arm A: Faricimab61.856.5 – 67.0
Arm B: Aflibercept54.048.7 – 59.3
Week 20
GroupValue95% CI
Arm A: Faricimab60.254.8 – 65.6
Arm B: Aflibercept55.550.0 – 60.9
Week 24
GroupValue95% CI
Arm A: Faricimab63.457.9 – 68.9
Arm B: Aflibercept53.648.0 – 59.3
Week 28
GroupValue95% CI
Arm A: Faricimab60.855.3 – 66.3
Arm B: Aflibercept61.455.8 – 67.0
Week 32
GroupValue95% CI
Arm A: Faricimab60.555.1 – 65.9
Arm B: Aflibercept56.450.8 – 62.0
Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time Secondary · Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combine

Week 4
GroupValue95% CI
Arm A: Faricimab78.974.5 – 83.2
Arm B: Aflibercept77.673.3 – 81.9
Week 8
GroupValue95% CI
Arm A: Faricimab80.776.4 – 84.9
Arm B: Aflibercept78.373.9 – 82.7
Week 12
GroupValue95% CI
Arm A: Faricimab84.280.3 – 88.1
Arm B: Aflibercept81.477.3 – 85.6
Week 16
GroupValue95% CI
Arm A: Faricimab84.880.9 – 88.7
Arm B: Aflibercept78.874.6 – 83.1
Week 20
GroupValue95% CI
Arm A: Faricimab80.876.5 – 85.2
Arm B: Aflibercept79.675.2 – 83.9
Week 24
GroupValue95% CI
Arm A: Faricimab81.977.5 – 86.3
Arm B: Aflibercept79.675.1 – 84.1
Week 28
GroupValue95% CI
Arm A: Faricimab77.873.1 – 82.6
Arm B: Aflibercept82.377.9 – 86.7
Week 32
GroupValue95% CI
Arm A: Faricimab78.774.2 – 83.1
Arm B: Aflibercept76.371.5 – 81.0
Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 Secondary · Baseline, average of Weeks 40, 44, and 48

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 l

Avoiding a Loss of ≥15 Letters
GroupValue95% CI
Arm A: Faricimab95.493.0 – 97.7
Arm B: Aflibercept94.191.5 – 96.7
Avoiding a Loss of ≥10 Letters
GroupValue95% CI
Arm A: Faricimab91.688.6 – 94.7
Arm B: Aflibercept92.089.1 – 95.0
Avoiding a Loss of ≥5 Letters
GroupValue95% CI
Arm A: Faricimab88.084.3 – 91.6
Arm B: Aflibercept86.883.0 – 90.5
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 Secondary · Baseline, average of Weeks 52, 56, and 60

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 l

GroupValue95% CI
Arm A: Faricimab93.991.3 – 96.5
Arm B: Aflibercept94.191.4 – 96.8
Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time Secondary · Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and \<33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., a

Week 4
GroupValue95% CI
Arm A: Faricimab97.695.9 – 99.2
Arm B: Aflibercept99.098.0 – 100.0
Week 8
GroupValue95% CI
Arm A: Faricimab97.696.0 – 99.2
Arm B: Aflibercept98.797.6 – 99.9
Week 12
GroupValue95% CI
Arm A: Faricimab98.296.7 – 99.6
Arm B: Aflibercept97.595.8 – 99.1
Week 16
GroupValue95% CI
Arm A: Faricimab98.196.7 – 99.6
Arm B: Aflibercept97.095.3 – 98.8
Week 20
GroupValue95% CI
Arm A: Faricimab97.495.7 – 99.1
Arm B: Aflibercept94.992.5 – 97.3
Week 24
GroupValue95% CI
Arm A: Faricimab97.295.3 – 99.1
Arm B: Aflibercept97.595.8 – 99.3
Week 28
GroupValue95% CI
Arm A: Faricimab95.993.8 – 98.1
Arm B: Aflibercept96.794.6 – 98.8
Week 32
GroupValue95% CI
Arm A: Faricimab95.493.1 – 97.7
Arm B: Aflibercept95.793.5 – 98.0

Adverse events — posted to ClinicalTrials.gov

Time frame: From first dose of study drug through end of study (up to 112 weeks). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm A: Faricimab
Serious: 80/333 (24%)
Deaths: 13/333
Arm B: Aflibercept
Serious: 93/336 (28%)
Deaths: 7/336

Serious adverse events (163 terms)

ReactionSystemArm A: FaricimabArm B: Aflibercept
Neovascular age-related macular degenerationEye disorders——
PneumoniaInfections and infestations——
Atrial fibrillationCardiac disorders——
CataractEye disorders——
COVID-19Infections and infestations——
Cardiac failure congestiveCardiac disorders——
Femur fractureInjury, poisoning and procedural complications——
DehydrationMetabolism and nutrition disorders——
DizzinessNervous system disorders——
SyncopeNervous system disorders——
EndophthalmitisInfections and infestations——
AnaemiaBlood and lymphatic system disorders——
Cardiac failureCardiac disorders——
Retinal pigment epithelial tearEye disorders——
Rhegmatogenous retinal detachmentEye disorders——
Abdominal painGastrointestinal disorders——
DiarrhoeaGastrointestinal disorders——
Gastrointestinal haemorrhageGastrointestinal disorders——
IleusGastrointestinal disorders——
Upper gastrointestinal haemorrhageGastrointestinal disorders——
AstheniaGeneral disorders——
Gait disturbanceGeneral disorders——
SepsisInfections and infestations——
Septic shockInfections and infestations——
Urinary tract infectionInfections and infestations——
Other adverse events (13 terms — click to expand)

ReactionSystemArm A: FaricimabArm B: Aflibercept
Neovascular age-related macular degenerationEye disorders——
Conjunctival haemorrhageEye disorders——
CataractEye disorders——
NasopharyngitisInfections and infestations——
Urinary tract infectionInfections and infestations——
Dry eyeEye disorders——
HypertensionVascular disorders——
Vitreous floatersEye disorders——
ArthralgiaMusculoskeletal and connective tissue disorders——
Vitreous detachmentEye disorders——
FallInjury, poisoning and procedural complications——
Eye painEye disorders——
Intraocular pressure increasedInvestigations——

Most-reported serious reactions: Neovascular age-related macular degeneration, Pneumonia, Atrial fibrillation, Cataract, COVID-19, Cardiac failure congestive, Femur fracture, Dehydration.

Data from ClinicalTrials.gov NCT03823287 adverse events section.

Sponsor's own description

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
    Heier JS, Khanani AM, Quezada Ruiz C, Basu K, et al · · 2022 · cited 528× · PMID 35085502 · DOI 10.1016/s0140-6736(22)00010-1
  2. Antibodies to watch in 2020.
    Kaplon H, Muralidharan M, Schneider Z, Reichert JM. · · 2020 · cited 332× · PMID 31847708 · DOI 10.1080/19420862.2019.1703531
  3. Antibodies to watch in 2022.
    Kaplon H, Chenoweth A, Crescioli S, Reichert JM. · · 2022 · cited 245× · PMID 35030985 · DOI 10.1080/19420862.2021.2014296
  4. Antibodies to watch in 2021.
    Kaplon H, Reichert JM. · · 2021 · cited 215× · PMID 33459118 · DOI 10.1080/19420862.2020.1860476
  5. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
    Khanani AM, Patel SS, Ferrone PJ, Osborne A, et al · · 2020 · cited 140× · PMID 32729897 · DOI 10.1001/jamaophthalmol.2020.2699
  6. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
    Khanani AM, Kotecha A, Chang A, Chen SJ, et al · · 2024 · cited 125× · PMID 38382813 · DOI 10.1016/j.ophtha.2024.02.014
  7. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H. · · 2020 · cited 95× · PMID 32111076 · DOI 10.3390/biom10030360
  8. Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases.
    Christopoulos PF, Gjølberg TT, Krüger S, Haraldsen G, et al · · 2021 · cited 86× · PMID 33912195 · DOI 10.3389/fimmu.2021.668207

Verify or expand the search:

Other trials of Faricimab

Trials testing the same drug.

Other recruiting trials for Wet Macular Degeneration

Currently open trials in the same condition.

Other Hoffmann-La Roche trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03823287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing